Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.

Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.

Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.

Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.

Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.

Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.

Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.

Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.

Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.

Abstract: Object The present invention provides a pharmaceutical composition for prophylaxis or treatment of hepatitis. Solution A pharmaceutical composition for prophylaxis or treatment of hepatitis, comprising a compound represented by the general formula (I): wherein R1 represents a C1-C4 alkyl group, R2 and R3 which are the same or different represent a hydrogen atom, a C1-C4 alkyl group, or a C1-C4 alkoxy group, X represents a sulfur atom or a nitrogen atom substituted by a methyl group, and n represents an integer of 3 or 4, or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: A pharmaceutical composition containing 1 or more PPAR regulators and 1 or more amino alcohol compounds of the formula (I): wherein R1 and R2, each represents hydrogen or alkyl; R3 represents C1-C6 alkyl or hydroxymethyl; R4 represents hydrogen, C1-C6 alkyl, alkoxy or halogen; R5 represents substituted phenyl; X represents vinylene (CH?CH), oxygen, sulfur or methylamino; Y represents a single bond, oxygen, sulfur or carbonyl; Z represents a single bond or C1-C8 alkylene; n represents 2 or 3; or pharmacologically acceptable salts thereof. The pharmaceutical composition is used to suppress rejection of organ transplants or skin grafts and to prevent or treat autoimmune diseases.

Abstract: A pharmaceutical composition useful as a preventive or therapeutic agent for immune-related diseases. The pharmaceutical composition includes at least HMG-COA reductase inhibitor and at least one amino alcohol compound having the following formula (I), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof wherein R1 and R2 each represents hydrogen; R3 represents lower alkyl or hydroxymethyl; R4 represents hydrogen, alkyl, alkoxy or halogen; R5 represents hydrogen, halogeno, cyclohexyl or phenyl; X represents vinylene (CH?CH), oxygen, sulfur or methylated nitrogen; Y represents a single bond, oxygen, sulfur or carbonyl; Z represents a single bond or C1-C8 alkylene; n is 2 or 3.